TCGA-E9-A54Y-01A-11R-A466-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.260
- MYC_TARGETS_V2+0.230
- OXIDATIVE_PHOSPHORYLATION+0.230
- DNA_REPAIR+0.180
- E2F_TARGETS+0.140
- ESTROGEN_RESPONSE_LATE+0.110
- SPERMATOGENESIS+0.110
- BILE_ACID_METABOLISM+0.030
- MYOGENESIS+0.020
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.020
Top 10 suppressed
- UV_RESPONSE_DN-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- TGF_BETA_SIGNALING-0.520
- PROTEIN_SECRETION-0.480
- INTERFERON_GAMMA_RESPONSE-0.450
- MITOTIC_SPINDLE-0.440
- ANDROGEN_RESPONSE-0.430
- ANGIOGENESIS-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- KRAS_SIGNALING_UP-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.931 |
| 2 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.913 |
| 3 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.905 |
| 4 | R233 | — | — | 0.899 |
| 5 | MDT-AP-2615 | Med | Medulloblastoma | 0.899 |
| 6 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.887 |
| 7 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.884 |
| 8 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.882 |
| 9 | ERR2278846 | — | — | 0.874 |
| 10 | TCGA-60-2726-01A-01R-0851-07 | — | cohortSQ1 | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |